ACER Acer Therapeutics Inc.

3.58
-0.04  -1%
Previous Close 3.62
Open 3.62
Price To Book 1.58
Market Cap 36,140,730
Shares 10,095,176
Volume 17,660
Short Ratio
Av. Daily Volume 43,701
Stock charts supplied by TradingView

NewsSee all news

  1. Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

  2. Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

    NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

  3. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Acer Therapeutics Inc. (NASDAQ:ACER) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934

  4. ACER IMMINENT DEADLINE: Rosen, A Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Acer Therapeutics Inc.; Important August 30th Deadline - ACER

    NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acer Therapeutics Inc. (NASDAQ:ACER)

  5. DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acer Therapeutics (NASDAQ: ACER) and Encourages Acer Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Acer Therapeutics,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued June 25, 2019.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
Pivotal bioavailability and bioequivalence trial Part A data due 4Q 2019; Part B due 1Q 2020 with NDA filing 1Q 2021.
ACER-001
Urea cycle disorder (UCD)
Phase 1/2 trial to be initiated mid-2020.
Osanetant
induced Vasomotor Symptoms (iVMS)

Latest News

  1. Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

  2. Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

    NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

  3. Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds investors that a purchaser of Acer Therapeutics Inc. (NASDAQ:ACER) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934

  4. ACER IMMINENT DEADLINE: Rosen, A Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Acer Therapeutics Inc.; Important August 30th Deadline - ACER

    NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Acer Therapeutics Inc. (NASDAQ:ACER)

  5. DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Acer Therapeutics (NASDAQ: ACER) and Encourages Acer Investors to Contact the Firm

    Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Acer Therapeutics,

  6. 2-DAY ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Acer Therapeutics, Inc.

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds Acer Therapeutics, Inc. (NASDAQ:ACER) ("Acer") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or

  7. FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

    NEW YORK, Aug. 27, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. ("Acer" or the

  8. Acer Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    NEWTON, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and

  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fred's, Acer Therapeutics, Diebold Nixdorf, and Intelligent Systems and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Fred's, Inc. (NASDAQ:FRED), Acer Therapeutics,

  10. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sunlands Technology Group, Fred's, Acer Therapeutics, and Ideanomics and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Sunlands Technology Group (NYSE:STG), Fred's,